The Impact of CYP2C19 and CYP4F2 Variants and Clinical Factors on Treatment Outcomes During Antiplatelet Therapy

References

• Valgimigli M , BuenoH , ByrneRAet al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J.39, 213–260 (2018).
   PubMed Web of Science ®Google Scholar
• Levine GN , BatesER , BittlJAet al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol.68, 1082–1115 (2016).
   PubMed Web of Science ®Google Scholar
• Wallentin L , BeckerRC , BudajAet al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , BraunwaldE , McCabeCHet al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357, 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Autors/Task Force Members , StegPG , JamesSK , AtarDet al.ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur. Heart J.33( 20), 2569–2619 (2012).
   PubMed Web of Science ®Google Scholar
• Hamm CW , BassandJP , AgewallSet al. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J.32, 2999–3054 (2011).
   PubMed Web of Science ®Google Scholar
• Authors/Task Force members , WindeckerS , KolhP , AlfonsoFet al.2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J.35(37), 2541–2619 (2014).
   PubMed Web of Science ®Google Scholar
• James SK , RoeMT , CannonCPet al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ342, d3527 (2011).
   PubMed Web of Science ®Google Scholar
• Bonaca MP , BhattDL , OudeOphuis Tet al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol.1, 425–432 (2016).
   PubMed Web of Science ®Google Scholar
• Costa F , van KlaverenD , JamesSet al. PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet389, 1025–1034 (2017).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O’ConnellJR , BlidenKPet al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA302, 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Trenk D , HochholzerW. Genetics of platelet inhibitor treatment. Br. J. Clin. Pharmacol.77, 642–653 (2014).
   PubMed Web of Science ®Google Scholar
• Grosdidier C , QuiliciJ , LoosveldMet al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am. J. Cardiol.111, 985–990 (2013).
   PubMed Web of Science ®Google Scholar
• Kenngott S , OlzeR , KollmerMet al. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur. J. Med. Res. 15, 220–224 (2010).
   PubMed Web of Science ®Google Scholar
• Kreutz RP , FlockhartDA. Amlodipine – not a significant contributor to clopidogrel non-response?Heart99, 437–439 (2013).
   PubMed Web of Science ®Google Scholar
• Tatarunas V , JankauskieneL , KupstyteNet al. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. Blood Coagul. Fibrinolysis25, 369–374 (2014).
   PubMed Web of Science ®Google Scholar
• Kupstyte N , ZaliunasR , TatarunasVet al. Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis. Pharmacogenomics16, 181–189 (2015).
   PubMed Web of Science ®Google Scholar
• Wallentin L , JamesS , StoreyRFet al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet376, 1320–1328(2010).
   PubMed Web of Science ®Google Scholar
• Varenhorst C , ErikssonN , JohanssonÅet al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur. Heart J.36, 1901–1912 (2015).
   PubMed Web of Science ®Google Scholar
• Storey RF , MelissaThornton Set al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets20, 341–348 (2009).
   PubMed Web of Science ®Google Scholar
• Tatarunas V , KupstyteN , ZaliunasR , GiedraitieneA , LesauskaiteV. The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. Pharmacogenomics18, 969–979 (2017).
   PubMed Web of Science ®Google Scholar
• Mehran R , RaoSV , BhattDLet al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation123, 2736–2747 (2011).
   PubMed Web of Science ®Google Scholar
• Cutlip DE , WindeckerS , MehranRet al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation115(17), 2344–2351 (2007).
   PubMed Web of Science ®Google Scholar
• Parodi G , StoreyRF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur. Heart J. Acute Cardiovasc. Care4, 555–560 (2015).
   PubMed Web of Science ®Google Scholar
• Thygesen K , AlpertJS , JaffeASet al. Fourth universal definition of myocardial infarction (2018). J. Am. Coll. Cardiol.72, 2231–2264 (2018).
   PubMed Web of Science ®Google Scholar
• Harding SA , HolleyA , WilkinsB , FairleyS , SimmondsM , LarsenPD. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?Intern. Med. J.47, 1298–1305 (2017).
   PubMed Web of Science ®Google Scholar
• Vercellino M , SànchezFA , BoasiVet al. Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. BMC Cardiovasc. Disord.17(1), 97 (2017).
   PubMedGoogle Scholar
• Tang X , LiR , JingQet al. Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J. Cardiovasc. Pharmacol.68(2), 115–120 (2016).
   PubMed Web of Science ®Google Scholar
• Dehghani P , LavoieA , LaviSet al. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patientsundergoing early PCI. Am. Heart J.192, 105–112 (2017).
   PubMed Web of Science ®Google Scholar
• Storey RF , BeckerRC , HarringtonRAet al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur. Heart J.32, 2945–2953 (2011).
   PubMed Web of Science ®Google Scholar
• Parker WA , BhattDL , PratsJet al. CHAMPION PHOENIX Investigators. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb. Haemost.117, 1093–1100 (2017).
   PubMed Web of Science ®Google Scholar
• Hagihara K , KazuiM , KuriharaAet al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab. Dispos.37, 2145–2152 (2009).
   PubMed Web of Science ®Google Scholar
• Tang M , MukundanM , YangJet al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther.319, 1467–1476 (2006).
   PubMed Web of Science ®Google Scholar
• Teng R , MayaJ , ButlerK. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets24, 615–624 (2013).
   PubMed Web of Science ®Google Scholar
• Pourdjabbar A , HibbertB , ChongAYet al. CAPITAL investigators. A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: a cautionary tale in managing patients with acute coronary syndromes. Int. J. Cardiol.214, 423–425 (2016).
   PubMed Web of Science ®Google Scholar
• Waldman M , PetersonSJ , AradM , HochhauserE. The role of 20-HETE in cardiovascular diseases and its risk factors. Prostaglandins Other Lipid Mediat.125, 108–117 (2016).
   PubMed Web of Science ®Google Scholar
• Hill E , FitzpatrickF , MurphyRC. Biological activity and metabolism of 20-hydroxyeicosatetraenoic acid in the human platelet. Br. J. Pharmacol.106, 267–274 (1992).
   PubMed Web of Science ®Google Scholar
• Kalsotra A , StrobelHW. Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol. Ther.112(3), 589–611 (2006).
   PubMed Web of Science ®Google Scholar
• Rotunno R , OppoI , SaettaG , AvetaP , BrunoS. NSAIDs and heart failure: a dangerous relationship. Monaldi Arch. Chest Dis.88, 950 (2018).
   PubMedGoogle Scholar
• Eikelboom JW , HirshJ , SpencerFA , BaglinTP , WeitzJI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest141(Suppl. 2), e89S–e119S (2012).
   PubMed Web of Science ®Google Scholar